Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the post-smtp domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/cwbk.umed.pl/public_html/wp-includes/functions.php on line 6114
TreatWolfram

TreatWolfram

Nazwa projektu: TreatWolfram

Tytuł projektu: An international, randomized, double-blinded, pivotal clinical trial with the aim to evaluate the efficacy and safety of sodium valproate in children and adults with Wolfram syndrome.

Główny badacz:

Kwota dofinansowania:

Nazwa projektu: Forma

Tytuł projektu: FORMA – a multicentre randomized-controlled trial to evaluate the efficacy and safety of ketoanalogues of essential amino acids in prophylaxis of protein-energy wasting in nephrotic syndrome.

Główny badacz:

Kwota dofinansowania: 9 605 089,78 PLN (including financing for UMED: 715 419,18 PLN)

Nazwa projektu: RemiRit

Tytuł projektu: RemiRit - Personalized immunosuppressive therapy with rituximab in the treatment of ANCA associated vasculitis - a randomized, multicenter clinical trial.

Główny badacz:

Kwota dofinansowania: 9 999 999.98 PLN (including financing for UMED: 833 293.80 PLN)

Nazwa projektu: RaRE-TS

Tytuł projektu: Multicenter, randomized, double-blind, placebocontrolledstudy to assess the efficacy and safety of Rapamycin in drug Resistant Epilepsy associated with TSC (RaRE-TS).

Główny badacz:

Kwota dofinansowania: 16 880 726,88 PLN (including financing for UMED: 3 611 233,02 PLN)

Nazwa projektu: ViRap

Tytuł projektu: Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with Tuberous Sclerosis Complex (ViRap).

Główny badacz:

Kwota dofinansowania: 23 119 125 PLN (including financing for UMED: 1 528 640,00 PLN)

share